← All drugs Report issue

Rozibafusp alfa

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Sep 1, 2011 (NCT01568203)

Timeline

2010s

Jan 1, 2011
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Schizophrenia · Phase 1

Mechanism of action

Tumor necrosis factor ligand superfamily member 13BINHIBITOR
TNFSF13B inhibitor
- Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) ↗
ICOS ligandINHIBITOR
ICOSLG inhibitor
- ICOS ligand (ICOSLG) ↗
Inducible T-cell costimulatorINHIBITOR
Inducible T-cell costimulator inhibitor
- Inducible T-cell costimulator (ICOS) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL4650245 ↗

Also known as

1-(4-(3-(4-(1h-benzo(d)imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone
amg 579
amg 579
amg 579
amg-579

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01568203	Phase 1	Sep 1, 2011	Amgen

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Amgen	For profit	1	1	1	2011

1 organizations

Page 1 / 1